SCHEMBL4380512

SCHEMBL4380512

CCCN1CCN(C(=O)C=Cc2ccc(O)cc2)CC1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR183 P32249 7/20 0.67
GAA P10253 1/20 0.58
ALDH1A1 P00352 3/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
ME2 P23368 1/20 0.54
ME1 P48163 1/20 0.54
ME3 Q16798 1/20 0.54
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
MAPT P10636 1/20 0.54
POLB P06746 1/20 0.54
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GRIN1 Q05586 1/20 0.52
GRIN2A Q12879 1/20 0.52
GRIN2B Q13224 1/20 0.52
GRIN2C Q14957 1/20 0.52
GRIN3A Q8TCU5 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
KDM4E B2RXH2 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14190905 1.00 GPR183 (0.67) GPR183GAAALDH1A1SMN1; SMN2ME2
SCHEMBL4384170 0.88 ALDH1A1 (0.68) GPR183GAAALDH1A1SMN1; SMN2MEN1
SCHEMBL13636191 0.88 ALDH1A1 (0.68) GPR183GAAALDH1A1SMN1; SMN2MEN1
SCHEMBL13636478 0.88 GPR183 (0.85) GPR183
SCHEMBL4377314 0.88 GPR183 (0.85) GPR183
SCHEMBL13636347 0.86 GPR183 (0.64) GPR183GAAALDH1A1SMN1; SMN2MEN1
SCHEMBL14190910 0.85 ALDH1A1 (0.67) GPR183GAAALDH1A1SMN1; SMN2MEN1
SCHEMBL4375408 0.85 ALDH1A1 (0.67) GPR183GAAALDH1A1SMN1; SMN2MEN1
SCHEMBL14190907 0.85 GPR183 (0.62) GPR183GAAALDH1A1SMN1; SMN2MEN1
SCHEMBL4383718 0.85 GPR183 (0.62) GPR183GAAALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP claimed
EP-1421071-B1 SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS HIGH POINT PHARMACEUTICALS LLC (US) 2009-11-18 EP disclosed
US-20080113968-A1 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2008-05-15 US disclosed
US-7208497-B2 Substituted piperazines and diazepanes NOVO NORDISK A/S (DK) 2007-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113968-A1 Substituted piperazines and diazepanes HRH3, HRH4, HRH1 GPR183 264/4885GAA 2830/4885ALDH1A1 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.